GRK 2873: Tools and Drugs of the Future - Innovative Methods and New Modalities in Medicinal Chemistry

GRK 2873：未来的工具和药物 - 药物化学的创新方法和新模式

• 批准号: 494832089
• 金额: --
• 依托单位: Rheinische Friedrich-Wilhelms-Universität Bonn
• 依托单位国家: 德国
• 项目类别: Research Training Groups
• 资助国家: 德国
• 项目状态: 未结题
• 来源: https://gepris.dfg.de/gepris/projekt/494832089?language=en
• 关键词: GRK; 2873; Tools; Drugs; Future

Medicinal Chemistry is a highly interdisciplinary field of research that focuses on the discovery, characterization and development of bioactive tool compounds and drugs. In recent years, the target landscape as well as the types of drug molecules (“drug modalities”) and the methods employed in Medicinal Chemistry and drug research have significantly changed. In the planned RTG we therefore intend to educate and train a future generation of medicinal chemists that will be well prepared to master future challenges. Different strategies will be employed to discover tools and drugs for novel types of targets. The research program focuses on four core themes that are closely interconnected: (I) targeted protein degraders (PROTACs), (II) macrocyclic drugs, (III) biopolymers as tools and drugs, and (IV) drug conjugates. The research projects are supported by jointly used technology platforms: the proprietary Pharma-Zentrum Bonn compound library, the Center of Aptamer Research and Development CARD, a structural biology platform, and a platform of advanced instruments in medicinal chemistry. This RTG proposal has been composed by leading researchers from five different institutes of two faculties (Faculty of Mathematics and Natural Sciences and Faculty of Medicine), who have a history of previous successful collaborations. The diverse group of PIs comprises experienced as well as young aspiring researchers. The broad scientific backgrounds of the researchers and their interconnections will allow us to gain considerable synergies in covering a wide variety of new modalities, all of which have in common that they differ from classical drugs: their properties are beyond Lipinski’s rule of 5 (Ro5) resulting in similar problems that have to be solved. The RTG will allow close interactions to tackle the resulting scientific questions. The University of Bonn and its surroundings, including industry partners, provide an ideal environment not only for research in Medicinal Chemistry, but also for translational drug development. We have planned a 3- to 4-year qualification program for the doctoral researchers. It comprises a lecture series in advanced medicinal chemistry, workshops, a central doctoral colloquium, an international lecture series and an international career development program comprising courses in soft skills, science philosophy and ethics in science. We will closely collaborate with our privileged international partner institutions, the Universities of Copenhagen (Denmark), Dundee (Scotland) and Tohoku (Japan) with which we have agreed on a lab exchange program for the doctoral students. We will innovate in key areas of medicinal chemistry and educate and train a new generation of medicinal chemists and young scientists at the interface between medicinal chemistry and interconnected disciplines. Moreover, the research projects will contribute to drug research and development for the benefit of patients.

药物化学是一个高度跨学科的研究领域，专注于生物活性工具化合物和药物的发现，表征和开发。近年来，药物化学和药物研究中采用的靶点和药物分子类型（“药物形式”）以及方法发生了显着变化。因此，在计划中的RTG中，我们打算教育和培训下一代药物化学家，他们将为应对未来的挑战做好充分准备。将采用不同的策略来发现针对新型靶点的工具和药物。该研究计划侧重于四个密切相关的核心主题：（I）靶向蛋白质降解剂（PROTAC），（II）大环药物，（III）作为工具和药物的生物聚合物，以及（IV）药物缀合物。这些研究项目得到了共同使用的技术平台的支持：专有的Pharma-Zentrum Bonn化合物库，适体研究和开发CARD中心，结构生物学平台和药物化学先进仪器平台。该RTG提案由来自两个学院（数学与自然科学学院和医学院）的五个不同研究所的主要研究人员组成，他们具有以前成功合作的历史。PI的多元化群体包括经验丰富的年轻有抱负的研究人员。研究人员的广泛科学背景及其相互联系将使我们能够在涵盖各种新形式方面获得相当大的协同作用，所有这些新形式都有一个共同点，即它们与经典药物不同：它们的特性超出了Lipinski的5规则（Ro 5），导致必须解决类似的问题。RTG将允许密切互动，以解决由此产生的科学问题。波恩大学及其周边地区，包括行业合作伙伴，不仅为药物化学研究提供了理想的环境，也为转化药物开发提供了理想的环境。我们计划为博士研究人员提供3至4年的资格课程。它包括高级药物化学系列讲座、研讨会、中央博士座谈会、国际系列讲座和国际职业发展计划，其中包括软技能、科学哲学和科学伦理课程。我们将与我们的特权国际合作伙伴机构，哥本哈根大学（丹麦），邓迪（苏格兰）和东北（日本），我们已经同意了博士生的实验室交流计划密切合作。我们将在药物化学的关键领域进行创新，并在药物化学与相互关联的学科之间教育和培训新一代药物化学家和年轻科学家。此外，这些研究项目将有助于药物研究和开发，造福患者。